



Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024

AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- [Lumos Pharma, Inc.](#) (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday, September 9th and 10th.

H.C. Wainwright 26th Annual Global Investment Conference: September 9th – 11th

Title:	Lumos Pharma Corporate Presentation (On-Demand)
Date/Time:	September 9 th at 7:00AM EDT
Webcast Link:	Register here
1x1 Meetings:	Monday-Tuesday, September 9 th -10 th

The presentation webcast can be downloaded at 7:00AM EDT on September 9th and will be available for 90 days thereafter. The webcast can also be accessed on the Company's website under [Events & Presentations](#) in the Investors & Media section. Please contact your H.C. Wainwright salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with management at the conference or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma's lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~\$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit <https://lumos-pharma.com/>.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com



Source: Lumos Pharma, Inc.